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ABSTRACT
Dietary consumption of high concentrations
of soybean products has been suggested to re-
duce the risk for prostate cancer (PCa). We con-
ducted a survey using patients with PCa to as-
sess the relationship between serum concentra-
tions of isoflavone aglycones and frequency of
soybean products consumption in patients with
PCa. We measured the serum concentrations of
daidzein, genistein, glycitein, and equol in 99
PCa patients, in addition to conducting a survey
using a selfadministrated questionnaire that in-
cluded the frequencies of various food item con-
sumptions. If serum concentrations of equol
were at a value less than 0.5 ng/mL, they were
classified as an equol nonproducer, and the
other patients were classified as equol produc-
ers. As a result, serum concentrations of
daidzein, genistein, and glycitein were found to
be significantly correlated to each other (P<
0.001). The frequency of tofu (soybean curd) con-
sumption was significantly correlated with the
serum concentration of daidzein (P<0.05). Like-
wise, the frequency of natto (fermented soy-
bean) consumption was significantly correlated
with the serum concentrations of daidzein, ge-
nistein, and glycitein (P<0.01). In the study there
were 40 equol producers and 59 equol nonpro-
ducers, but none of the food items were signifi-
cantly different between the equol producers
and the equol nonproducers. We have a plan to
perform a similar survey for populationbased
controls in the future. Comparisons between the
data of the PCa patients and the controls would
give us more information about the role of isofla-
vones and equol production in regard to the risk
of PCa.
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INTRODUCTION
Dietary consumption of high concentrations
of soy products has been epidemiologically sug-
gested to reduce the risk for prostate cancer
(PCa)1,2). Isoflavone aglycones such as daidzein,
genistein, and glycitein have also been shown to
prevent PCa in vitro studies37). Furthermore,
equol, the metabolite of daidzein in gut mi-
croflora, has been indicated to have potent anti
carcinogenic effects on PCa as well8,9).
We conducted this survey using patients
with PCa to assess the relationship between se-
rum concentrations of isoflavone aglycones and
the frequency of soy product consumption in pa-
tients with PCa. We also assessed whether die-
tary habits would influence the metabolism of
isoflavones in soybean products, because the
previous articles1015) reported that some dietary
habits might be related to equol production in
human gut microflora.
METHODS
There were 168 PCa patients who visited
the Department of Urology, Sapporo Medical
University from January, 2007 to April, 2008.
We excluded 26 patients from the study, be-
cause 5 patients died, 19 patients were in too
poor health, 1 subject moved out of the Hok-
kaido Prefecture, and 1 subject was not Japa-
nese. Among the residual 142 patients, informed
consent was obtained from 117 patients (82.3%),
and their sera were collected. Their concentra-
tions of isoflavone aglycones such as daidzein,
genistein, glycitein and equol were measured by
the LCMS methods (SRL Co., Tokyo). If their
concentrations of equol were at a value less
than 0.5 ng/mL, they were classified as an equol
nonproducer. The other patients whose equol
concentrations were at a value higher than or
equal to 0.5 ng/mL, they were classified as
equol producers. Furthermore, all of the 117 pa-
tients also fulfilled the selfadministrated ques-
tionnaire which included items about frequen-
cies of consumption for 28 foods and their life-
style habits over the period of one or two years
before their diagnosis.
The average age at the time of diagnosis of
the 117 patients with PCa was 69.4 years (stan-
dard deviation or SD; 6.4 years; Range; 53.682.2
years). The average interval between the date
of the diagnosis and filling out the questionnaire
was 1.5 years (SD; 1.1 years; Range 0～7.3
years), and the average interval between the
date of taking the sera and filling out the ques-
tionnaire was 35.0 days (SD; 35.7 days; Range; 0
～157 days). Among them, 79 patients had been
operated on with a radical prostatectomy, 34 pa-
tients had been treated with radiation, and 14
patients had been treated with hormone ther-
apy.
Furthermore, 18 patients had cancer in
other sites such as the stomach (6 cases) or in-
testine (3 cases). We excluded these 18 patients
from the analysis because of a possibility in mal-
nutrition. Eventually, we analyzed the data of 99
PCa patients. The software SAS (ver. 9.2) was
used for the analysis. The significance level was
set at a 5% level.
RESULTS
As shown in Table 1, the median (ng/mL)
of daidzein, genistein, glycitein, and equol were
118.9, 134.5, 3.3; and a value less than 0.5, respec-
tively. As the Spearman's correlation coeffi-
cients are shown in Table 2, serum concentra-
tions of daidzein, genistein, and glycitein were
significantly correlated to each other (P<0.001).
However, the serum concentration of equol was
Table １．Distribution in serum levels of isoflavone aglycones among the 99 prostate cancer patients.
Median (ng／mL) Range (ng／mL)
Daidzein ７２．４ １．３９６７．２
Genistein １３４．５ ３．２２１３４．７
Glycitein ３．３ ０．５４８．８
Equol a value less than ０．５ a value less than ０．５１６４．２
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not correlated with any serum concentration of
daidzein, genistein, or glycitein.
As shown in Table 3, the frequency of tofu
(soybean curd) consumption was significantly
correlated with serum concentrations of
daidzein (P<0.05). Likewise, the frequency of
natto (fermented soybean) consumption was sig-
nificantly correlated with serum concentrations
of daidzein, genistein, and glycitein (P<0.01).
Frequencies of other soybean product consump-
tion such as miso soup, fried soybean curd
(aburage), sprouted soybean (moyashi), green
soybean (edamame), and (soybean milk) were
not correlated with any serum concentrations of
isoflavone aglycone.
Under our classification there were 40
equol producers and 59 equol nonproducers.
We compared the frequencies of various food
item consumptions between the equol produc-
ers and the equol nonproducers, and calculated
the odds ratios and their 95% confidence inter-
vals adjusting age with the logistic regression
model. As shown in Table 4, none of the food
items were significantly different between the
equol producers and the equol nonproducers.
DISCUSSION
Frequencies of soybean curd or fermented
soybean consumption in PCa patients one or
two years before the diagnosis were signifi-
cantly correlated with serum concentrations of
daidzein, genistein, and glycitein. These results
suggest that dietary habits might have lasted
even after the diagnosis of cancer was made.
Dietary habits have been suggested to in-
fluence the metabolism of isoflavones and the
production of equol1015). Setchell and Cole13)
showed that the proportion of equol producers
in vegetarians was 59%, similar to the reported
frequency in Japanese adults consuming soy-
bean products, and much higher than that for
nonvegetarian adults. Lampe et al.14) also re-
ported that higher dietary fibers and plant pro-
tein, less fat, and more carbohydrate intakes
have been associated more strongly with equol
producers than equol nonproducers among fe-
male patients. Miyanaga et al.15) have suggested
that higher consumption of soybean products
and green tea can enhance equol production.
On the contrary, Zhao et al.16) did not show
any correlation between the equol excretion and
intakes of food items among Japanese patients.
Table ３．The Spearman's correlation coefficients between serum levels of isoflavone aglycones
and frequency of soybean product consumptions among the 99 prostate cancer pa-
tients.
Table ２．The Spearman's correlation coefficients in serum levels of isoflavone aglycones
among the 99 prostate cancer patients.
Daidzein Genistein Glycitein
Genistein ０．９２７＊＊＊  
Glycitein ０．９１５＊＊＊ ０．８１７＊＊＊ 
Equol ０．０５５ ０．０１３ ０．０３３
＊＊＊： P＜０．００１
Food items Daidzein Genistein Glycitein Equol
Miso soup ０．１１８ ０．０５６ ０．０８５ ０．１９３
Soybean curd (Tofu) ０．２１４＊ ０．１８１ ０．１５７ ０．０４２
Fermented soybean (Natto) ０．３０２＊＊ ０．２８５＊＊ ０．３０９＊＊ ０．０２５
Fried soybean curd (Aburage) ０．０３１ ０．０３１ ０．００８ ０．１２３
Sprouted soybean (Moyashi) ０．０４３ ０．０４２ ０．０９３ ０．０５２
Green soybeans (Edamame) ０．０９０ ０．０５２ ０．０４１ ０．０１１
Soy milk (Tonyu) ０．０９８ ０．０５８ ０．１０３ ０．０１７
＊＊： P＜０．０１ ＊： P＜０．０５
43（２００８） Serum isoflavone concentrations in patients with prostate cancer ２７
Our results did not exhibit any association be-
tween the equol producers and the equol non
producers either. One of the reasons for such no
association may be that most Japanese patients
eat soybean products, and therefore, the differ-
ences were reduced.
Our data of serum concentrations in PCa
patients were collected during nonfasting peri-
ods rather than during fasting periods. More-
over, some of the cases had been treated with
radiation or hormonal therapy. These factors
might have influenced the serum concentrations
of isoflavones.
Because our data about frequencies of vari-
ous food item consumptions were focused on
dates one or two years before the diagnosis, it
could be possible that recall bias might have ex-
isted. In the future we plan to perform a similar
survey for populationbased controls who do
not have any cancer. Comparison between the
data of PCa patients and the controls would
give us more information about the role of
isoflavones and equol production in regard to
the risk of PCa.
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Food items OR＃ ９５％CI
Chiken ０．７６ ０．４７１．２４
Beef or pork ０．６４ ０．３８１．０８
Ham，sousage ０．７２ ０．４５１．１４
Fish １．００ ０．７０１．４３
Seaweed ０．８６ ０．６５１．１６
Miso soup １．２３ ０．９４１．６０
Soybean curd (Tofu) ０．９９ ０．６６１．４０
Fermented soybean (Natto) ０．９７ ０．７５１．２５
Fried soybean curd (Aburage) ０．８０ ０．５０１．２７
Sprouted soybean (Moyashi) １．１４ ０．７２１．８１
Green soybeans (Edamame) ０．９０ ０．５１１．６１
Soy milk (Tonyu) ０．９２ ０．６４１．３１
Carrot ０．９６ ０．６８１．３４
Broccori １．０７ ０．７８１．４６
Tomato ０．９５ ０．７３１．２３
Green or yellow vegetables １．００ ０．７８１．２８
White vegetables １．２２ ０．９１１．６４
Orange ０．９８ ０．７５１．２８
Other fruits ０．８４ ０．６４１．０９
Milk １．００ ０．８２１．２１
Yogurt ０．８９ ０．７２１．１０
Green tea １．０２ ０．８６１．２１
Coffee １．０３ ０．８６１．２４
Black tea ０．７６ ０．５３１．０９
＃： Odds ratio per １ order among ８ orders of frequency of food consumption．
２８ M．MORI et al.
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